B. Riley Securities Downgrades Fusion Pharmaceuticals to Neutral, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Yuan Zhi downgraded Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Neutral but increased the price target from $13 to $23.

March 20, 2024 | 2:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Fusion Pharmaceuticals was downgraded by B. Riley Securities from Buy to Neutral, though the price target was raised from $13 to $23.
The downgrade to Neutral suggests a more cautious outlook on FUSN's short-term growth prospects or valuation, potentially limiting upside momentum. However, the significant increase in the price target from $13 to $23 indicates a positive revision of the company's longer-term financial health or market position. This mixed signal could lead to neutral short-term price movement as investors weigh the downgrade against the higher price target.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90